PeptidePedia The community reference

Special:RecentChanges

Change log·7,183 revisions·page 34 of 72

Every change to PeptidePedia Wiki, newest first. N marks a new page, m a minor edit and b an edit by an approved bot. The byte figure is the page size after the edit; the coloured figure is the change. 7,183 changes are logged in total.

7,183Logged changes
598Bot edits
175Page creations
256Active editors

30 August 2025

  1. (diff | hist) m 18:39 SinoPep 8,064 +707 BatchNumberBede (talk | contribs) fix hyphenation per PP:MOS [rollback]
  2. (diff | hist) 09:26 Talk:Temperature excursion 1,170 +229 LabelLibby (talk | contribs) /* In-use allowance table: which jurisdiction? */ reply
  3. (diff | hist) m 01:17 Dual incretin agonist 5,851 +485 CuriousCallum (talk | contribs) label the animal data as animal data in the sentence, not only in the section heading [rollback]

29 August 2025

  1. (diff | hist) 10:44 Nantong Guangyuan Chemical 14,195 ±0 TelehealthTruus (talk | contribs) convert the product range to a table so the documentation column lines up [rollback]
  2. (diff | hist) 10:14 Talk:Temperature excursion 959 +312 PharmDrafts (talk | contribs) /* In-use allowance table: which jurisdiction? */ reply
  3. (diff | hist) 08:59 Beyond-use date 19,030 +876 UnitAuditUwe (talk | contribs) clarify that the figure is per dose, not per vial [rollback]
  4. (diff | hist) 08:37 VendorInvestigate 5,067 ±0 VerifyFirstVida (talk | contribs) expand §Use on this wiki [rollback]
  5. (diff | hist) m 05:21 Growth hormone secretagogue 4,495 ±0 MOTSc_Mira (talk | contribs) expand §Material in research supply [rollback]

28 August 2025

  1. (diff | hist) 23:19 Mass spectrometry 5,612 ±0 Chromatokid (talk | contribs) add the ionisation mode to the mass-spectrometry description [rollback]
  2. (diff | hist) 22:29 Amylin 5,099 ±0 CuriousCallum (talk | contribs) expand §Amyloid formation [rollback]
  3. (diff | hist) m b 22:22 WuXi TIDES 14,644 ±0 CategoryBot (talk | contribs) bot: update parent category chain [rollback]
  4. (diff | hist) 18:30 Shenzhen Hybio Pharmaceutical 2,847 ±0 DrTitration (talk | contribs) add the see-also to the certificate-of-analysis article [rollback]
  5. (diff | hist) m 16:04 Sterility testing 4,776 +338 RotationRosalind (talk | contribs) rm the claim that the method is stability-indicating without a forced-degradation study [rollback]
  6. (diff | hist) m 14:37 Body composition assessment 4,901 ±0 CarryOverCai (talk | contribs) add the pre-analytical requirement: tube type and time to separation [rollback]
  7. (diff | hist) m 13:29 Subcutaneous injection 5,293 ±0 ThymosinTamsin (talk | contribs) state that reconstituted material should not be frozen, with the source [rollback]
  8. (diff | hist) 12:22 TRIUMPH trial programme 4,549 ±0 PioneerPerdita (talk | contribs) expand §Status and caution [rollback]
  9. (diff | hist) m b 10:09 Exenatide 5,531 ±0 CategoryBot (talk | contribs) bot: sort category members [rollback]
  10. (diff | hist) m 08:35 Area percent purity 7,380 ±0 SatietySunniva (talk | contribs) clarify that mass spectrometry confirms identity, not purity [rollback]
  11. (diff | hist) m 07:58 Shanghai Wibson Biotechnology 10,235 +485 GroupBuyGalen (talk | contribs) clarify that no manufacturing or marketing authorisation is claimed or established [rollback]
  12. (diff | hist) m 04:09 Liquid chromatography-mass spectrometry 4,276 ±0 EndotoxinEd (talk | contribs) clarify that mass spectrometry confirms identity, not purity [rollback]
  13. (diff | hist) 03:47 STEP trial programme 5,534 +283 SurpassSunniva (talk | contribs) name the funder in the sentence, per PP:MOS [rollback]
  14. (diff | hist) 03:26 Repackaging 4,759 +253 PrepHPLC_Pia (talk | contribs) fix the anchor on an internal link [rollback]
  15. (diff | hist) 03:13 LEADER trial 4,799 +628 FlowTrialFraser (talk | contribs) expand §Place in the evidence [rollback]

27 August 2025

  1. (diff | hist) m 23:34 List of GLP-1 receptor agonists 3,862 +231 SeeAlsoSelma (talk | contribs) add the column header that was missing [rollback]
  2. (diff | hist) m 22:37 Reference standard 5,217 ±0 AnalyticalAnnie (talk | contribs) copyedit [rollback]
  3. (diff | hist) m 17:52 Melanotan II 4,374 ±0 INN_Ingrid (talk | contribs) add see also to the closely related analogue [rollback]
  4. (diff | hist) m 17:18 Chinese Peptide Company 14,113 +226 PBM_Perrin (talk | contribs) add the standing talk-page note link to the banner [rollback]
  5. (diff | hist) 16:52 Talk:Temperature excursion 748 +325 ColdChainCleo (talk | contribs) /* In-use allowance table: which jurisdiction? */ reply
  6. (diff | hist) m 16:31 ChinaPeptides 12,567 +60 RetatrutideRuben (talk | contribs) add the note that self-published material is usable only for what it states about itself [rollback]
  7. (diff | hist) m 15:08 Receptor bias 4,477 +477 AmylinAmos (talk | contribs) expand §Status of the idea [rollback]
  8. (diff | hist) 14:19 Talk:Temperature excursion 537 +267 LabelLibby (talk | contribs) /* In-use allowance table: which jurisdiction? */ new section
  9. (diff | hist) 11:27 Test report forgery 5,391 +336 eGFR_Esme (talk | contribs) add the citation for the blind-sampling discussion [rollback]
  10. (diff | hist) 08:57 Cold chain 24,029 ±0 ChainCustodyChad (talk | contribs) add the collapse-temperature point, sourced [rollback]
  11. (diff | hist) 07:58 Flourishglobal Peptide Biotech 9,573 +819 FmocFrancis (talk | contribs) expand §Regulatory position and legal status [rollback]
  12. (diff | hist) m 07:44 Albumin binding half-life extension 6,399 +378 GIP_Genoveva (talk | contribs) add the citation for the co-secretion finding [rollback]
  13. (diff | hist) m b 04:24 Contract development and manufacturing organisation 4,794 ±0 ArchiveBot (talk | contribs) bot: normalise temperature formatting [rollback]
  14. (diff | hist) m 02:38 Temperature excursion 14,171 +272 FreightFenna (talk | contribs) state the residual-moisture target with the method it is measured by [rollback]
  15. (diff | hist) 00:58 Preparative HPLC purification 4,882 ±0 FlowTrialFraser (talk | contribs) attribute the stability figure to the study and its duration [rollback]

26 August 2025

  1. (diff | hist) 22:59 USP General Chapter 71 4,657 +587 UnitAuditUwe (talk | contribs) rm the assertion that two laboratories must agree; they need not [rollback]
  2. (diff | hist) 17:15 Survodutide 5,302 ±0 OralSemaOswin (talk | contribs) expand §Design and rationale [rollback]
  3. (diff | hist) 16:01 Peptide aggregation 5,516 +322 IsocraticIla (talk | contribs) add the ionisation mode to the mass-spectrometry description [rollback]
  4. (diff | hist) 15:29 Reverse-phase HPLC 5,499 ±0 AnalyticalAnnie (talk | contribs) rm the claim that the method is stability-indicating without a forced-degradation study [rollback]
  5. (diff | hist) m 15:10 Sigma-Aldrich (Shanghai) Trading 12,550 +413 ReportReaderRilla (talk | contribs) move a stray full stop inside the reference [rollback]
  6. (diff | hist) 12:41 Blind sampling 8,193 +326 LotTraceLuka (talk | contribs) expand §What blinding is for [rollback]
  7. (diff | hist) 09:30 Talk:Semaglutide 1,370 +140 ConsensusConal (talk | contribs) /* Requested move: → Semaglutide (drug) */ reply
  8. (diff | hist) 09:04 Insulin syringe 4,944 ±0 GlossaryGleb (talk | contribs) add the sharps-disposal cross-link [rollback]
  9. (diff | hist) 06:38 Tianjin Finder Chemical 12,456 +1,700 TallySheetTad (talk | contribs) correct the trading name — the short code and the legal name are different things [rollback]

25 August 2025

  1. (diff | hist) 22:20 Crude peptide 4,546 ±0 IncretinIvo (talk | contribs) clarify that "cold chain" without a logger is a claim, not a record [rollback]
  2. (diff | hist) 15:01 Regulatory status by jurisdiction 4,444 +182 ImportRecordIna (talk | contribs) add the patent-expiry statement, attributed and dated [rollback]
  3. (diff | hist) 14:16 SURMOUNT trial programme 4,721 ±0 NNT_Nerys (talk | contribs) the article attributed a finding to the wrong trial in the programme [rollback]
  4. (diff | hist) 03:55 Reconstitution calculator 8,369 ±0 SchemaSorcha (talk | contribs) clarify which figures are measured and which are derived [rollback]

24 August 2025

  1. (diff | hist) 15:04 Peptide 6,813 +204 CustomsClarke (talk | contribs) state the difference between a validated shipper and an insulated box [rollback]
  2. (diff | hist) 11:48 Guangzhou JEEP Biotechnology 13,849 +798 BetaCellBoyd (talk | contribs) add the outbound storefront link, marked nofollow and sponsored per the external-links convention [rollback]
  3. (diff | hist) 06:56 Intention-to-treat analysis 4,963 ±0 StudentSindhu (talk | contribs) cite the trial publication rather than the sponsor press release [rollback]
  4. (diff | hist) m 01:10 Global access disparity 4,275 ±0 SchematicScout (talk | contribs) expand §Consequences and framing [rollback]

23 August 2025

  1. (diff | hist) m 23:54 Hunan Aslsen Technology 12,908 +207 ReportReaderRilla (talk | contribs) expand §Reception [rollback]
  2. (diff | hist) 23:14 Shanghai ERP Biotechnology 5,367 ±0 BlankVialBo (talk | contribs) add the catalogue size and label it self-reported [rollback]
  3. (diff | hist) m b 15:06 Insulin syringe unit conversion 6,290 +205 ArchiveBot (talk | contribs) bot: normalise citation format [rollback]
  4. (diff | hist) 14:05 Shenzhen Hybio Pharmaceutical 2,847 ±0 LotTraceLuka (talk | contribs) attribute the capability claim to the organisation's own material [rollback]
  5. (diff | hist) 10:51 Shanghai Sigma-Audley New Material Technology 13,175 +1,081 SafetySignalSid (talk | contribs) expand §Operations and documentation practice [rollback]
  6. (diff | hist) m b 06:18 Research use only 7,724 ±0 CategoryBot (talk | contribs) bot: sort category members [rollback]
  7. (diff | hist) m b 03:52 Weight regain after discontinuation 4,670 +46 CiteBot (talk | contribs) bot: sort category members [rollback]
  8. (diff | hist) m 03:21 Sangon Biotech 12,139 +592 EndotoxinEd (talk | contribs) add the note that self-published material is usable only for what it states about itself [rollback]
  9. (diff | hist) 02:08 Contraindications of incretin therapy 4,842 ±0 IncretinIvo (talk | contribs) add the citation for the gallbladder finding [rollback]
  10. (diff | hist) 00:10 Good manufacturing practice 5,123 ±0 API_Aurora (talk | contribs) add the date the shortage listing ended [rollback]

22 August 2025

  1. (diff | hist) m 20:54 Incretin effect 7,134 ±0 SatietySunniva (talk | contribs) add category for receptor pharmacology [rollback]
  2. (diff | hist) 19:07 Solid-phase peptide synthesis 5,359 ±0 BPC_Bramwell (talk | contribs) give the closure integrity test by name [rollback]
  3. (diff | hist) 16:21 Beta cell function 6,096 +345 Chromatokid (talk | contribs) add a figure for the secretion time course and caption it [rollback]
  4. (diff | hist) 10:54 Peptide content 8,131 ±0 NPOV_Nadia (talk | contribs) expand §What occupies the rest of the mass [rollback]
  5. (diff | hist) 09:55 Talk:Reconstitution calculator 1,096 +118 UnitsUrsula (talk | contribs) /* Dead space: delivered dose or vial yield? */ reply
  6. (diff | hist) 07:39 Glucagon-like peptide-1 12,102 ±0 DrTitration (talk | contribs) the half-life given was for the intact peptide; label it [rollback]

21 August 2025

  1. (diff | hist) 22:37 Timeline of incretin therapeutics 4,460 ±0 OrforglipronOona (talk | contribs) fix a broken wikilink [rollback]
  2. (diff | hist) 20:32 Prescribing information 4,506 ±0 HarmReductionHen (talk | contribs) correct the population figure — the source gives eligible, not treated [rollback]
  3. (diff | hist) m 15:56 Trial data comparison 6,038 +235 ConsensusConal (talk | contribs) expand §Why the estimand matters [rollback]
  4. (diff | hist) 15:47 Talk:Reconstitution calculator 885 +186 SyringeSybille (talk | contribs) /* Dead space: delivered dose or vial yield? */ reply
  5. (diff | hist) 14:38 Zhuhai Kerui Biotechnology 6,892 +144 DiagramDelphine (talk | contribs) clarify that a registered business scope is a licensing fact, not a quality assurance [rollback]
  6. (diff | hist) 11:03 Drug master file 4,325 +233 TrialsTabitha (talk | contribs) attribute the compounding statement to the pharmacy board that issued it [rollback]
  7. (diff | hist) 10:51 Customs seizure 4,516 ±0 TrialsTabitha (talk | contribs) correct the description of the research-use-only exemption [rollback]
  8. (diff | hist) 10:14 Talk:Reconstitution calculator 674 +374 DeadSpaceDot (talk | contribs) /* Dead space: delivered dose or vial yield? */ new section
  9. (diff | hist) 09:44 Talk:Qingdao Saber Technology Pharmaceutical 1,170 +108 BalanceBirdie (talk | contribs) /* Appearance and purity are separate observations */ reply
  10. (diff | hist) 08:28 Triple agonist 4,269 +282 ComparisonCato (talk | contribs) state plainly that the research-use-only form is not approved for human use [rollback]
  11. (diff | hist) m 06:49 Patent expiry and biosimilars 4,183 ±0 LabRangeLindy (talk | contribs) clarify that personal importation and commercial importation are different questions [rollback]
  12. (diff | hist) 02:29 Qingdao Saber Technology Pharmaceutical 6,613 +1,063 BatchNumberBede (talk | contribs) typo [rollback]

20 August 2025

  1. (diff | hist) 23:37 Lyophilisation 26,375 +1,596 Chromatokid (talk | contribs) add the reconstitution-stability sentence with its storage condition [rollback]
  2. (diff | hist) 21:27 Semaglutide 9,799 ±0 DulaglutideDug (talk | contribs) add the discontinued indication with its date [rollback]
  3. (diff | hist) 16:00 Retatrutide 7,261 ±0 SemaglutideSasha (talk | contribs) state the substitution in one-letter code as well, per PP:MOS [rollback]
  4. (diff | hist) m 15:02 MOTS-c 4,435 ±0 ThymosinTamsin (talk | contribs) give the sequence in one-letter code with the modifications spelled out [rollback]
  5. (diff | hist) 13:08 Karl Fischer titration 9,318 +577 Areapercent_Ayo (talk | contribs) rm the claim that the method is stability-indicating without a forced-degradation study [rollback]
  6. (diff | hist) 12:44 Talk:Semaglutide 1,159 +231 ManualOfStyleMo (talk | contribs) /* Requested move: → Semaglutide (drug) */ reply
  7. (diff | hist) m 10:20 Peptide stability table 5,688 +282 TelehealthTruus (talk | contribs) correct a transposed pair of values in the comparison table [rollback]
  8. (diff | hist) 10:05 Talk:Semaglutide 948 +156 DisambigDenzil (talk | contribs) /* Requested move: → Semaglutide (drug) */ new section
  9. (diff | hist) 08:55 Talk:Qingdao Saber Technology Pharmaceutical 959 +232 EndotoxinEd (talk | contribs) /* Appearance and purity are separate observations */ reply
  10. (diff | hist) 05:51 Peptide supply chain 8,147 ±0 ReportReaderRilla (talk | contribs) clarify that the cake appearance is an indicator, not a specification [rollback]
  11. (diff | hist) m 05:24 Sarcopenia 4,239 +477 CPeptidePaddy (talk | contribs) space between number and unit per PP:MOS [rollback]
  12. (diff | hist) 04:09 Cold-chain freight 4,370 ±0 FlowTrialFraser (talk | contribs) add the data-logger point: an unlogged shipment has no excursion record [rollback]
  13. (diff | hist) 02:34 CagriSema 5,302 ±0 GradientGus (talk | contribs) expand §Formulation considerations [rollback]

19 August 2025

  1. (diff | hist) 20:12 SinoPep 7,357 +1,379 DrTitration (talk | contribs) alphabetise the see-also list [rollback]
  2. (diff | hist) m 18:23 Electrospray ionisation 4,323 +250 HyphenHarriet (talk | contribs) add the sample preparation, since the result depends on it [rollback]
  3. (diff | hist) 14:07 Talk:Qingdao Saber Technology Pharmaceutical 748 +324 Chromatokid (talk | contribs) /* Appearance and purity are separate observations */ reply
  4. (diff | hist) 10:28 Talk:Qingdao Saber Technology Pharmaceutical 537 +218 BalanceBirdie (talk | contribs) /* Appearance and purity are separate observations */ new section